Skip to main content
main-content

Neurology

Occipital GABA levels reduced in Parkinson’s patients with visual hallucinations

MRI image_Brain

Reduced levels of γ-aminobutyric acid in the primary visual cortex are linked to visual hallucinations in patients with Parkinson’s disease, study findings indicate.

09-08-2018 | Multiple sclerosis | News | Article

Lower risk of disability progression in primary progressive versus progressive-relapsing MS

Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis, suggest the results of an observational cohort study published in JAMA Neurology.

Source:

JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.210

03-08-2018 | Parkinson's disease | News | Article

Apomorphine infusion reduces ‘off time’ in patients with Parkinson’s disease

Subcutaneous apomorphine infusion meaningfully reduces the time in which a patient’s medication is not working optimally and parkinsonian symptoms return, reports the placebo-controlled, multicentre TOLEDO trial.

Source:

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30239-4
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30284-9

27-07-2018 | Parkinson's disease | News | Article

Occipital GABA levels reduced in Parkinson’s patients with visual hallucinations

Reduced levels of γ-aminobutyric acid in the primary visual cortex are linked to visual hallucinations in patients with Parkinson’s disease, study findings indicate.

Source:

Neurology 2018; doi:10.1212/WNL.0000000000006007
Neurology 2018; doi:10.1212/WNL.0000000000005985

Twitter Icon Follow medwireNews

Click here
image credits